We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that it has extended its collaboration agreement with Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) .
Key Aspects of the Collaboration
Both the companies will work together to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.
The companies plan to advance programs directed to 30 targets. Other candidates also might be introduced into clinical development during the initial five-year discovery period, which includes an option to extend.
Regeneron will lead development and commercialization for all programs targeting eye diseases, while Alnylam will be entitled to potential milestone and royalty payments.
Both the companies will work together and take turns for CNS programs. The lead party will retain its global development and commercial responsibilities.
Regeneron and Alnylam will also select a number of RNAi therapeutic programs, which target genes expressed in the liver and can influence a wide variety of diseases affecting different body parts. Both the companies will evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases. These include evaluating Regeneron's pozelimab (REGN3918), currently in phase I development, with Alnylam's cemdisiran, currently in phase II development. Per the terms, Alnylam will retain control of cemdisiran monotherapy development, while Regeneron will lead the development of the combination. Both the companies will equally share investment and potential future profits on the monotherapy program and Alnylam will receive royalties on any potential combination product sales. Regeneron and Alnylam will alternate leadership and participate equally in potential profits for all other alliance liver programs.
We remind investors that both the companies collaborated to identify RNAi therapeutics for the chronic liver disease, nonalcoholic steatohepatitis (NASH), and potentially other related diseases in 2018. Both the companies will continue to work on the same as part of this expanded collaboration.
Financial Terms of the Transaction
Regeneron will make a $400-million upfront payment to Alnylam. The former will also purchase $400 million of Alnylam equity at $90.00 per share (4.44 million common shares), based on the volume-weighted average price over the last fifteen-trading-day period.
Additionally, Alnylam is eligible to receive up to an additional $200 million in milestone payments.
Regeneron will provide Alnylam with $2.5 million in funding at the initiation of any program and an additional $2.5 million for identifying the lead candidate. Alnylam will also get an additional $30 million in annual discovery funding.
Our Take
The collaboration with Alnylam will give Regeneron an option to have a pipeline based on RNAi technology. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. The technology promises potential.
The FDA approved the first ever RNAi therapeutic, Alnylam’s Onpattro, for the treatment of the polyneuropathy of hATTR amyloidosis in adults in the United States and that in adults with Stage 1 or Stage 2 polyneuropathy in the EU. The collaboration will provide Alnylam with funds and a strong partner like Regeneron.
At the same time, the collaboration extension will boost Regeneron’s pipeline, as its lead drug Eylea, which is approved for various ophthalmology indications, is likely to face competitive threats. The company also has a collaboration agreement with Bayer (BAYRY - Free Report) for the same.
Regeneron’s stock has gained 5.1% in the past six months against the industry’s decline of 3.2%.
Concurrently, Alnylam announced that it will terminate its research agreement with Sanofi (SNY - Free Report) . Both the companies have agreed to conclude the research and option phase of their RNAi therapeutics collaboration for rare genetic diseases. Additionally, Alnylam and Sanofi have agreed to amend certain terms of the companies’ equity agreement, with the latter obtaining a release of its lock-up of Alnylam stock holdings.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that it has extended its collaboration agreement with Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) .
Key Aspects of the Collaboration
Both the companies will work together to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.
The companies plan to advance programs directed to 30 targets. Other candidates also might be introduced into clinical development during the initial five-year discovery period, which includes an option to extend.
Regeneron will lead development and commercialization for all programs targeting eye diseases, while Alnylam will be entitled to potential milestone and royalty payments.
Both the companies will work together and take turns for CNS programs. The lead party will retain its global development and commercial responsibilities.
Regeneron and Alnylam will also select a number of RNAi therapeutic programs, which target genes expressed in the liver and can influence a wide variety of diseases affecting different body parts. Both the companies will evaluate anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases. These include evaluating Regeneron's pozelimab (REGN3918), currently in phase I development, with Alnylam's cemdisiran, currently in phase II development. Per the terms, Alnylam will retain control of cemdisiran monotherapy development, while Regeneron will lead the development of the combination. Both the companies will equally share investment and potential future profits on the monotherapy program and Alnylam will receive royalties on any potential combination product sales. Regeneron and Alnylam will alternate leadership and participate equally in potential profits for all other alliance liver programs.
We remind investors that both the companies collaborated to identify RNAi therapeutics for the chronic liver disease, nonalcoholic steatohepatitis (NASH), and potentially other related diseases in 2018. Both the companies will continue to work on the same as part of this expanded collaboration.
Financial Terms of the Transaction
Regeneron will make a $400-million upfront payment to Alnylam. The former will also purchase $400 million of Alnylam equity at $90.00 per share (4.44 million common shares), based on the volume-weighted average price over the last fifteen-trading-day period.
Additionally, Alnylam is eligible to receive up to an additional $200 million in milestone payments.
Regeneron will provide Alnylam with $2.5 million in funding at the initiation of any program and an additional $2.5 million for identifying the lead candidate. Alnylam will also get an additional $30 million in annual discovery funding.
Our Take
The collaboration with Alnylam will give Regeneron an option to have a pipeline based on RNAi technology. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. The technology promises potential.
The FDA approved the first ever RNAi therapeutic, Alnylam’s Onpattro, for the treatment of the polyneuropathy of hATTR amyloidosis in adults in the United States and that in adults with Stage 1 or Stage 2 polyneuropathy in the EU. The collaboration will provide Alnylam with funds and a strong partner like Regeneron.
At the same time, the collaboration extension will boost Regeneron’s pipeline, as its lead drug Eylea, which is approved for various ophthalmology indications, is likely to face competitive threats. The company also has a collaboration agreement with Bayer (BAYRY - Free Report) for the same.
Regeneron’s stock has gained 5.1% in the past six months against the industry’s decline of 3.2%.
Concurrently, Alnylam announced that it will terminate its research agreement with Sanofi (SNY - Free Report) . Both the companies have agreed to conclude the research and option phase of their RNAi therapeutics collaboration for rare genetic diseases. Additionally, Alnylam and Sanofi have agreed to amend certain terms of the companies’ equity agreement, with the latter obtaining a release of its lock-up of Alnylam stock holdings.
Zacks Rank
Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>